ACTINEER
Live / Registered — Registered (as of 01 Apr 2025)
What this means for you
Registered since 01 Apr 2025. The owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 79397582
- Registration number
- 7741628
- Mark type
- Design + words
- Filed
- 08 Feb 2024
- Published for opposition
- 11 Feb 2025
- Registered
- 01 Apr 2025
- Attorney of record
- Kari Moyer-Henry
Goods and services
- Class 001 — Chemicals: Chemical substances, chemical materials and chemical preparations for use in the manufacture of medical products; chemical substances, chemical materials and chemical preparations for use in the manufacture of radiopharmaceutical products; chemical raw materials, in particular actinium-225 radiochemical, for the formulation of radiopharmaceutical products; chemical raw materials, in particular bismuth-213, for the formulation of radiopharmaceutical products
- Class 005 — Pharmaceuticals: Radiopharmaceutical diagnostic preparations for medical purposes; radiopharmaceutical diagnostic preparations for pharmaceutical purposes; radiopharmaceutical therapeutic preparations for medical purposes; radiopharmaceutical therapeutic preparations for pharmaceutical purposes, in particular radiopharmaceutical preparations for endo-radionuclide therapy, brachytherapy, positron emission tomography, single photon emission computed tomography, target radionuclide therapy and peptide receptor radionuclide therapy; radiopharmaceutical preparations, in particular actinium-containing radiopharmaceutical products in GMP quality; radiopharmaceutical preparations, in particular bismuth-containing radiopharmaceutical products in GMP quality; radiopharmaceutical preparations for use in oncology, in particular radiopharmaceuticals containing radioisotopes, in particular actinium-225; radiopharmaceutical preparations for use in oncology, in particular radiopharmaceuticals containing radioisotopes, in particular bismuth-213; radiopharmaceuticals containing medical radioisotopes with longer half-lives, in particular actinium-225 for the treatment of tumour diseases; radiopharmaceuticals containing medical radioisotopes with longer half-lives, in particular bismuth-213 for the treatment of tumour diseases; target radiopharmaceuticals containing a target molecule, in particular peptide , depending on the indication, and a medical radioactive isotope; target radiopharmaceuticals containing a target molecule, in particular an antibody depending, on the indication, and a medical radioactive isotope; radiopharmaceuticals containing actinium-225 and its complexes; radiopharmaceuticals containing bismuth-213 and its complexes
- Class 010 — Medical apparatus: Medical instruments, apparatus and containers for the production of radiopharmaceutical preparations, namely sample preparation devices automatically or manually operated in particular for the production of actinium-225 in GMP quality; medical instruments, apparatus and containers for the production of radiopharmaceutical preparations, namely sample preparation devices automatically or manually operated in particular for the production of bismuth-213 in GMP quality; control, regulation and measuring apparatus as parts of medical instruments, apparatus and containers, in particular devices containing fluidic processing components as valves, small vessels (5-500 ml) and purification columns for the production of a radiotherapeutic or radiodiagnostic substance, in particular for the production of actinium-225 in GMP quality; control, regulation and measuring apparatus as parts of medical instruments, apparatus and containers included in this class, in particular devices containing fluidic processing components as valves, small vessels (5-500 ml) and purification columns for the production of a radiotherapeutic or radiodiagnostic substance, in particular for the production of bismuth-213 in GMP quality; radionuclide generator for radiopharmaceutical purpose
- Class 042 — Scientific and technological services: Scientific and technological services and research relating to the use of actinium-225, in particular medical and pharmacological research services relating to the use of actinium-225; scientific and technological services and research relating to the use of bismuth-213, in particular medical and pharmacological research services relating to the use of bismuth-213; scientific and technological services and research relating to the use of other alpha emitters, in particular medical and pharmacological research services relating to the use of other alpha emitters
- Class 044 — Medical, beauty and agricultural services: Medical services, in particular medical services relating to radiotherapeutic and radiodiagnostic oncology, cardiology, angiology, neuroradiology, nuclear medicine and brachytherapies, namely intercavitary, interstitial and intravascular brachytherapy, radionuclide labelling, PET and SPECT scanning and radionuclide therapy, peptide receptor radionuclide therapy, personal nuclear medicine and precision oncology; medical services for theranostics in the field of precision oncology
Owner
Prosecution history
- 30 Nov 2025 — NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
- 12 Nov 2025 — NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
- 12 Nov 2025 — NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
- 31 Oct 2025 — FINAL DECISION TRANSACTION PROCESSED BY IB
- 15 Oct 2025 — FINAL DISPOSITION NOTICE SENT TO IB
- 14 Oct 2025 — FINAL DISPOSITION PROCESSED
- 02 Jul 2025 — FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
- 01 Apr 2025 — NOTICE OF REGISTRATION CONFIRMATION EMAILED
- 01 Apr 2025 — REGISTERED-PRINCIPAL REGISTER
- 11 Feb 2025 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 11 Feb 2025 — PUBLISHED FOR OPPOSITION
- 05 Feb 2025 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 21 Jan 2025 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 30 Dec 2024 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 30 Dec 2024 — CORRESPONDENCE RECEIVED IN LAW OFFICE